

Correction to “An Unexpected Deuterium-Induced Metabolic Switch in Doxophylline”

Silvio Aprile, Giorgia Colombo, Marta Serafini, Rosanna Di Paola, Federica Pisati, Irene Preet Bhela, Salvatore Cuzzocrea, Giorgio Gerosa, and Tracey Pirali*

ACS Med. Chem. Lett. 2022, 13 (8), 1278–1285. DOI: 10.1021/acsmmedchemlett.2c00166



Cite This: ACS Med. Chem. Lett. 2023, 14, 1891–1892



Read Online

ACCESS |

 Metrics & More

 Article Recommendations

In the original published version of this article, Figure 6g included an incorrect image. The correct image is as follows:

Published: November 27, 2023






Figure 6. Model of pulmonary fibrosis induced by bleomycin. Doxophylline and *d*₇-doxophylline attenuate BLM-induced structural damage and lung fibrosis in mice. (a) Representative scheme of BLM-induced lung injury model. (b) Total BAL cellularity of sham (not treated mice) and bleomycin-treated mice (treated or not with 80 mg/kg doxophylline, *d*₄-doxophylline, or *d*₇-doxophylline). Mean \pm SEM of 3 independent experiments. (c) Wet/dry lung weight ratio of sham and bleomycin-treated mice (treated or not with 80 mg/kg doxophylline, *d*₄-doxophylline, or *d*₇-doxophylline). Mean \pm SEM of 3 independent experiments. (d) MPO activity in lungs of sham and bleomycin-treated mice (treated or not with 80 mg/kg doxophylline, *d*₄-doxophylline, or *d*₇-doxophylline). Mean \pm SEM of 3 independent experiments. (e) Representative images of hematoxylin and eosin staining of sham and bleomycin-treated mice (treated or not with 80 mg/kg doxophylline, *d*₄-doxophylline, or *d*₇-doxophylline). (f) Representative images of Masson's trichrome staining and (g) Picrorius red staining of sham and bleomycin-treated mice (treated or not with 80 mg/kg doxophylline, *d*₄-doxophylline, or *d*₇-doxophylline). *p* value: * $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$; **** $p < 0.0001$.